@inproceedings{inproceedings, title = {{Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels}},
url = {{}},
year = {{2021}},
month = {{1}},
author = {{Cork MJ and Wollenberg A and Siegfried EC and Arkwright PD and Chen Z and Levit NA and Marco AR and Radwan A}},
volume = {{51}},
journal = {{CLINICAL AND EXPERIMENTAL ALLERGY}},
issue = {{12}},
pages = {{1659-1659}},
note = {{Accessed on 2025/07/13}}}